Cellectar Biosciences, Inc. Logo

Cellectar Biosciences, Inc.

Clinical-stage biopharma developing targeted cancer treatments via a PDC platform.

CLRB | US

Overview

Corporate Details

ISIN(s):
US15117F8077
LEI:
Country:
United States of America
Address:
100 CAMPUS DRIVE, 7932 FLORHAM PARK

Description

Cellectar Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted cancer treatments. The company's core technology is a proprietary Phospholipid Drug Conjugate (PDC) platform that selectively delivers therapeutic payloads, such as radioisotopes and cytotoxins, to cancer cells by targeting lipid rafts in their plasma membranes. This approach is designed to maximize antitumor activity while minimizing off-target effects on healthy tissue. Cellectar's lead product candidate is iopofosine I 131, a first-in-class PDC that delivers the radioisotope iodine-131. It is being developed for the treatment of hematologic malignancies and has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for Waldenstrom's Macroglobulinemia.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Cellectar Biosciences, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Cellectar Biosciences, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Cellectar Biosciences, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

CYTOKINETICS INC Logo
A late-stage biopharma developing drugs for diseases of impaired muscle function.
United States of America
CYTK
CytomX Therapeutics, Inc. Logo
Clinical-stage oncology company developing conditionally activated biologics.
United States of America
CTMX
Cytori Cell Research Institute,Inc. Logo
Develops cell therapy medical devices using a patient's own adipose tissue.
Japan
3750
Daebonglsco.,Ltd Logo
Develops and supplies raw materials for the pharmaceutical, cosmetic, and food industries.
South Korea
078140
DaehanPharmaceutical Logo
Researches, develops, and manufactures human/animal pharma and bio-pharmaceuticals.
South Korea
023910
DAE HWA PHARM CO., LTD Logo
Pharmaceutical firm developing drugs with proprietary drug delivery system technologies.
South Korea
067080
Daesung Microbiological Labs. Co. Ltd Logo
Develops, manufactures, and distributes animal pharmaceuticals and vaccines.
South Korea
036480
DAEWON PHARMACEUTICAL CO.,LTD Logo
Develops and manufactures prescription drugs and finished pharmaceutical products.
South Korea
003220
DAEWOONG CO.,LTD Logo
A holding company in the biotech and healthcare sectors developing pharmaceuticals.
South Korea
003090
DAEWOONG PHARMA Logo
Develops and manufactures drugs, biologics, and active pharmaceutical ingredients.
South Korea
069620

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.